|
|
 | | | |
- close
- close
- close
- close
DUSA Pharmaceuticals (DUSA) |
QUOTE AND NEWS
Globe Newswire
May 8
Comment
Q1 Domestic PDT Revenues Up 26% Year-Over-Year; Company Achieves Record Domestic BLU-U® Sales Volumes Conference Call and Audio Webcast Will Be Held Today, May 8th, at 8:30am EDT WILMINGTON, Mass., May 8, 2012 (GLOBE NEWSWIRE) -- DUSA
Globe Newswire
May 1
Comment
WILMINGTON, Mass., May 1, 2012 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc. (Nasdaq:DUSA) announces that its first quarter 2012 corporate highlights and financial results press release will be issued on Tuesday, May 8th at 6:30 a.m. to be followed
Globe Newswire
Apr 24
Comment
WILMINGTON, Mass., April 24, 2012 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc.® (Nasdaq:DUSA), a dermatology company that is developing and marketing its Levulan® Photodynamic Therapy (PDT) platform, announced today that patient enrollment is
Globe Newswire
Apr 10
Comment
WILMINGTON, Mass., April 10, 2012 (GLOBE NEWSWIRE) -- Dermatology company DUSA Pharmaceuticals, Inc.® (Nasdaq:DUSA), today introduced its Teeing Off Against Sun Damage™ campaign. This campaign will focus on educating consumers about the importance
Globe Newswire
Mar 23
Comment
WILMINGTON, Mass., March 23, 2012 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc.® (Nasdaq:DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), previously announced that Bob Doman, President and Chief
Globe Newswire
Mar 16
Comment
Campaign and New Website www.spotsignsofAK.com Launched Today During American Academy of Dermatology Annual Meeting WILMINGTON, Mass., March 16, 2012 (GLOBE NEWSWIRE) -- Dermatology company DUSA Pharmaceuticals, Inc.® (Nasdaq:DUSA), introduced an
Globe Newswire
Mar 7
Comment
WILMINGTON, Mass., March 7, 2012 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc.® (Nasdaq:DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), announced that Bob Doman, President and Chief Executive
MarketWatch
Mar 6
Comment
Shares of DUSA Pharmaceuticals soared 20% to $5.62 Tuesday after the company reported a higher quarterly profit. Analysts at C.K. Cooper initiated coverage of the stock with a buy rating, while Roth Capital analyst Scott Henry raised his price...
Benzinga
Mar 6
Comment
According to a research report published earlier today, C.K. Cooper has initiated coverage on DUSA Pharmaceuticals Inc.(NASDAQ: DUSA) with a Buy rating and $8 PT.
In the report, C.K. Cooper commented, “We expect a blow-out fourth quarter...
Globe Newswire
Feb 8
Comment
WILMINGTON, Mass., Feb. 8, 2012 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc.® (Nasdaq:DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), announced that Bob Doman, President and Chief Executive
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
